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Summary — Animals are still widely used in drug development and safety tests, despite evidence for their
lack of predictive value. In this regard, we recently showed, by producing Likelihood Ratios (LRs) for an
extensive data set of over 3,000 drugs with both animal and human data, that the absence of toxicity in
animals provides little or virtually no evidential weight that adverse drug reactions will also be absent in
humans. While our analyses suggest that the presence of toxicity in one species may sometimes add evidential weight for risk of toxicity in another, the LRs are extremely inconsistent, varying substantially for
different classes of drugs. Here, we present further data from analyses of other species pairs, including nonhuman primates (NHPs), which support our previous conclusions, and also show in particular that test
results inferring an absence of toxicity in one species provide no evidential weight with regard to toxicity
in any other species, even when data from NHPs and humans are compared. Our results for species including humans, NHPs, dogs, mice, rabbits, and rats, have major implications for the value of animal tests in
predicting human toxicity, and demand that human-focused alternative methods are adopted in their place
as a matter of urgency.
Key words: animal tests, dog, drug development, monkey, mouse, non-human primate, preclinical
testing, rabbit, rat, toxicology.
Address for correspondence: Jarrod Bailey, Cruelty Free International (formerly BUAV), 16a Crane
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Introduction
Preclinical trials or ‘animal tests’ on new drugs are
required by regulatory agencies worldwide (e.g. 1, 2),
based on a presumption of human relevance and
predictability, rather than robust scientific evidence
(3). This requirement continues, even in the face of
record levels of drug failure and drug attrition (4–7),
as well as evidence that reveals the animal tests to
be unfit for purpose. This evidence includes our two
recent analyses, in which a data set on an unprecedented scale, of published adverse events in multiple
species, induced by well over 2,000 pharmaceuticals,
was used to apply the evidential weight provided by
animal tests to the probability that a new drug may
be toxic (or not toxic) to humans (8, 9). These studies
revealed two main points: first, that toxicity in animals may be likely to also be present in humans,
though this cannot be considered particularly consistent or reliable, due to considerable variability
and lack of any clear pattern in types of toxic effects;
and secondly, perhaps more crucially, that the
absence of toxicity in animals provides essentially no
insight into the likelihood of toxicity or absence of
toxicity in humans.
To augment these studies, which examined the
contribution of tests on dogs, rats, mice and rabbits

to predicting human risk, we have now analysed
further data from non-human primates (NHPs) —
arguably the most likely non-human species to
have significant human relevance — asking the
same question. In addition, we have examined the
relationships of data from other pairs of these five
non-human species, to assess how reliably tests in
one species can indicate the toxicological susceptibility of any other species to new drugs. Our
hypothesis is that this is not possible, since major
interspecies differences mean that the interspecies
extrapolation of toxicity risk is inevitably poor,
whatever the species, including humans.
Once again, we have used the most apposite statistical metrics in our approach — Likelihood
Ratios (LRs) — which, unlike ‘concordance’ metrics, such as the True Positive Rate (sensitivity) or
Positive Predictive Value (PPV), directly address
the salient issue of the contribution of evidential
weight by a test in one species for or against the
toxicity of a given compound in another species.

Methods
A detailed consideration and description of the
diagnostic metrics used in this analysis can be
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found in our first two reports (8, 9). Briefly, the
data analysed were obtained from Instem
Scientific Limited (Harston, Cambridge, UK;
http://www.instem-lss.com; Safety Intelligence
Programme). All the data were collated by Instem
from publicly available sources, including: PubMed
(http://www.ncbi.nlm.nih.gov/pubmed), the FDA
Adverse Event Reporting System (FAERS),
DrugBank (http://www.drugbank.ca), and the
National Toxicology Program (http://ntp.niehs.
nih.gov), for a total of 3,028 ‘single active ingredients’ (excluding combination drugs) in humans and
preclinical species. The effects of each compound
were classified by Instem according to their target
tissues (e.g. bradycardia and arrhythmic disorder
would both be considered to be effects on heart tissues), based on five levels of specificity classified
by their MedDRA (Medical Dictionary for Regulatory Activities; http://www.meddramsso.com)
counterparts, ranging from any of the (more than
70,000) very specific Low Level Terms (LLT, e.g.
‘feeling queasy’) up to very generic System Organ
Class (SOC), such as ‘gastrointestinal disorders’.
These classifications help to eliminate false positives that may arise from species-specific observations, as well as in the identification of concordant
observations that might otherwise have been
missed, by their ‘rolling up’ into more-generic
terms. Where it was not possible for such MedDRA
mapping to be achieved, the preferred term of
Instem’s own Safety Intelligence Programme (SIP)
knowledge base (e.g. ‘musculoskeletal toxicity’)
was used instead.
For each compound, the presence or absence of
toxicity was logged for each species of each ‘species
pair’ being examined. These results were recorded
in a standard 2 × 2 matrix of results (see Table 1),
allowing various diagnostic metrics to be derived.
The rationale for our use of LRs, as opposed to positive concordance rate or PPV, has been described
previously (8, 9); in short, LRs — both positive
(PLR) and inverse negative (iNLR) — are the only
approaches that include both sensitivity and specificity, i.e. that are sufficient to measure the evidential weight provided by each test in question.
Sensitivity alone is insufficient: if, for instance, an
animal test always indicates toxicity present in

Table 1:

humans, it has a sensitivity of 100%. However, if
that test, in addition, always indicates toxicity,
even when it is absent in humans, every drug
tested may as well be dismissed as toxic to humans
at the outset, so knowledge of that test’s specificity
is also necessary. Further, PPV is conditional and
depends on the prevalence of toxicity in the compounds, and so is inappropriate (e.g. 10, 11).
With reference to the 2 × 2 results matrix (Table
1), PLR is given by: sensitivity/(1 – specificity) = (a /
a + c)/(b / b + d), while iNLR = specificity/(1 – sensitivity) = (d / b + d)/(c / a + c). All the values were
calculated by using the above formulae, in
Microsoft Excel® worksheets containing the data.
PLR and iNLR capture the ability of one animal
species to add evidential weight to the belief that a
specific compound is toxic/non-toxic in another,
respectively. As McGee (12) has emphasised, “LRs
may range from 0 to infinity. Findings with LRs
greater than 1 argue for the diagnosis of interest;
the bigger the number, the more convincing [the
finding]. Findings whose LRs lie between 0 and 1
argue against the diagnosis of interest; the closer
the LR is to 0, the less likely [the finding]. Findings
whose LRs equal 1 lack diagnostic value”. Note
that, where McGee states, “argue [for/against] the
diagnosis of interest” (as he is discussing the role
of LRs in evaluating the performance of a
diagnostic test clinically), we can replace this
phrase with ‘support the evidential value of the
animal test’.
Any animal species that gives a PLR/iNLR that
is statistically significantly higher than 1.0, can
therefore be regarded as contributing some degree
of evidential weight to the probability that the
compound under test will be toxic/non-toxic in the
other species. Crucially, these definitions imply
that, if any particular animal species is ‘good’ at
predicting toxicity in another, it is not necessarily
also good for predicting an absence of toxicity. That
is, a high PLR does not guarantee a high iNLR.
The full set of Instem Scientific data on which this
analysis is based, including 95% Confidence
Intervals, are available on request from the author
for correspondence.
A discussion of potential bias in the LR estimates is provided in the previous papers (8, 9),

A 2 × 2 matrix of results

Compound toxic in animal model
Compound not toxic in animal model

Compound toxic
in humans

Compound not
toxic in humans

a: true positives (TPs)

b: false positives (FPs)

c: false negatives (FNs)

d: true negatives (TNs)

Predicting human drug toxicity via animal tests

which should be consulted for a fuller explanation.
Briefly, the data set is probably affected by selection bias/effect, given that drugs that appear
highly toxic in rodent tests are unlikely to advance
to tests in dogs, NHPs and humans. This means
that these types of drugs will be under-represented
in the data set, so the LRs will not exactly represent the population of drugs as a whole. This will
be true of all data sets, however, as this precautionary principle is an inherent aspect of the testing protocol. In these circumstances, anybody
conducting an analysis such as this will be faced
with an identical situation, and this is acknowledged (see 8, 9). Gauging the actual contribution of
animal data to human toxicology is therefore virtually impossible. All one can do is to take steps to
minimise the effects of bias. We have taken such
steps. The data set was limited to drugs in the
FAERS database, and so all the compounds had
proceeded to market, and animal and human data
were available for them. The only way in which
publication bias can be addressed is for the industry, as the holders of significant amounts of unpublished data, to either conduct its own
investigations, and/or to facilitate such investigations by third parties. The latter could be achieved
by making anonymised data available for analysis,
in accordance with the promotion of transparency
cited in Directive 2010/63/EU (13).

Results
The total number of classifications of effects for
each species pair examined, and therefore the
numbers of LRs calculated initially for each
species pair, are shown in Table 2a. It should be
noted that a large proportion of the data reflected
adverse events that are rare, potentially compromising the reliability of any analysis of it. A moredetailed consideration of this point is provided in
our previous paper (8). To take account of this, rare
events were removed from consideration, and the
LRs were recalculated. This was done for rare
events at various thresholds, namely, less than 2,
5, 10 and 20 events. The number of classifications
used in our analysis for each of these thresholds is
shown in Table 2b.
Median PLRs and iNLRs, involving the entire
data set for each species pair (i.e. with no classifications containing rare observations removed), in
each direction (i.e. ‘mouse for rat’ and ‘rat for
mouse’), are shown in Table 3a. Almost all the values show the evidential weight provided by an animal test in one species for toxicity/lack of toxicity
in another species to be zero (the exceptions being
the rat–mouse pairs). These conclusions, however,
must be affected by the predominance of rare
observations in the data set, as mentioned above.
For example, 97% of the classifications were dis-
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counted for the NHP–human species pair, when
accounting for rare observations (< 2; see Table 2),
due to the extremely low numbers of observations
in one or more species. The recalculated LRs, at
four different thresholds with classifications containing rare events removed, are depicted graphically in Figure 1. The PLR and iNLR values for the
‘< 5’ threshold, at which any classifications in the
data set that contained observations of toxicity in
either species that numbered fewer than five were
discounted, are listed in Table 3b. This threshold
was chosen, as it has served as a basis for removing the potential bias caused by the inclusion of
rare observations in previous analyses, and is the
cut-off point used by the data provider, Instem.
The range of LRs (both PLRs and iNLRs) for each
species pair, also with rare LRs (< 5 observations)
removed from the data set, is shown in Figure 2.
All the PLRs were generally quite high (though
not dramatically so, bearing in mind that LRs may
have values up to infinity), particularly for the
rat–mouse pairs, suggesting that compounds
showing toxicity in one species are also likely to be
toxic in the other. This includes the NHP–human
species pair. Notably, however, these are significantly lower than median PLRs for the dog, mouse,
rabbit and rat with respect to humans, reported in
our previous analyses (8, 9). However, in common
with these previous reports, high ranges, with no
obvious pattern of toxicity, suggest the reliability
of this aspect cannot be generalised or regarded
with confidence. Crucially, median iNLRs were
substantially lower than PLRs, and were barely
greater than unity, supporting the view that, when
toxicity appears to be absent in one species, this
result provides essentially no evidential weight to
the likelihood of lack of toxicity in any other
species. As for PLRs, this includes the NHP–
humans species pair.
It has been put to us that it may be difficult to
appreciate the significance of our results, given
that LRs can extend to infinity. In other words,
what, for instance, do PLRs of approximately 10,
20 or 50 actually mean? We have tried to provide a
rough, though relevant, ‘yardstick’ by taking data
from the comparison of the two most-commonly
used preclinical species (rat and dog), and comparing the rat with itself, and the dog with itself.
Clearly, the LRs from these ‘control’ comparisons
were always going to have infinite values, as a
data set must show absolute identity with itself.
We therefore factored in a small percentage of FP
and FN values (0.1% of the total sample size for
each observation, in the dog–rat data set with rare
events [< 5] removed, to derive a value for a hypothetical inter-species ‘self’ comparison that is not
perfect, but which shows a high level of identity.
The PLR for the hypothetical rat–rat pair was 898,
and for the dog–dog 845. The iNLRs were 17.3 and
6.6, respectively. While these values are artificial,
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56
58
55
50
57
57

59
65
64
65
83
83

Species pair

NHP–human

NHP–dog
Dog–NHP
NHP–rat
Rat–NHP
NHP–mouse
Mouse–NHP

Dog–rat
Rat–dog
Dog–mouse
Mouse–dog
Rat–mouse
Mouse–rat

1119
1238
829
854
2779
2565

394
405
495
626
493
530

483

Biomedical
observations
(BMOs)

1178
1303
893
919
2862
2648

450
463
550
676
550
587

527

Total
classifications
used

PLR

7772
7647
4402
4376
6842
7056

1791
1778
7965
7839
4022
3985

16,230

Classifications
eliminated

86
59
83
64
83
86

63
58
86
51
82
57

86

Tissuelevel
effects

8263
1675
4227
1781
3875
8137

1814
724
8428
619
4250
722

16,563

Biomedical
observations
(BMOs)

8349
1734
4310
1845
3958
8223

1877
782
8514
670
4332
779

16,649

Total
classifications
used

iNLR

601
7216
985
3450
5746
1481

364
1459
1
7845
240
3793
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Classifications
eliminated

8950
8950
5295
5295
9704
9704

2241
2241
8515
8515
4572
4572

16,757

Total

The total number of classifications used in the analysis is shown in columns 3 and 7 (Total classifications used; PLR and iNLR respectively), which comprise the sum
of column 1 (PLR) or 5 (iNLR) (tissue-level effects) and column 2 (PLR) or 6 (iNLR) (BMOs). The number of BMO classifications for which there were no effects
observed in the ‘test’ species of interest, and which were therefore eliminated from consideration in our analysis, are shown in columns 4 (PLR) and 8 (iNLR)
(Classifications eliminated), out of the total number of classifications for which there were data. In total, data were available for 3,028 ‘active pharmaceutical
ingredients’.

The number of classifications of effects for each species pair, and therefore the numbers of LRs calculated for each species pair, are shown: the total number of
classifications the data provided (column 9), as well as those data able to be used to calculate both PLR (columns 1–4), and iNLR (columns 5–8). Note that each pair is
shown bi-directionally (e.g. dog–rat and rat–dog), for reasons described in the text; briefly, the test hypothesis was: ‘Does species 2 predict/add value to species 1?’, so
each pair had to be done in both directions. The exception was the ‘NHP–human’ pair, as we are not interested in to what degree humans predict/add value to NHP
toxicity (Row 1 of results).

Tissuelevel
effects

a) The total number of classifications

Table 2: The number of classifications of adverse effects for each species pair, as used in this analysis
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159

214
237
247
638
471
1500

NHP–human

NHP–dog
NHP–rat
NHP–mouse
Dog–rat
Dog–mouse
Rat–mouse

86
64
89
312
223
688

37

<5

43
25
46
166
108
304

9

< 10

19
3
16
76
54
131

3

< 20

2241
8515
4572
8950
5295
9704

16,757

Total

The number of observations for which data were discounted is shown at the head of the columns. As the numbers were identical for each species pair, regardless of the
‘direction’; (see Table 2a legend), only one pair is shown, which may be assumed to be ‘bi-directional’. The most stringent approach (< 10 and < 20) can be considered
illustrative only; for practical purposes, < 5 has been used previously, and is used by Instem (the data provider) as a cut-off point. The relatively low numbers of ‘nonrare’ observations for species pairs involving NHPs (and indeed the absolute low numbers of observations when, for example, less than 20 observations are discounted)
is evidence of the difficulty in accessing NHP toxicology data, of which little is publicly-available.

<2

Number of classifications used in analysis when ‘Rare Observations’ discounted

The number of classifications of adverse effects for each species pair, as used in this analysis, with rare events (fewer than two, five, ten, or twenty in either or both
species) removed from the data set

continued

Species pair

b)

Table 2:
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Figure 1: PLRs and iNLRs for all species pairs, for all four thresholds below which rare events
were removed from the data set
a) Median PLR values
50

40

Median PLR

30

20

= NHP–dog
= NHP–human
= NHP–mouse
= NHP–rat
= dog–mouse
10

= dog–NHP
= dog–rat
= mouse–dog
= mouse–NHP
= mouse–rat
= rat–dog
= rat–mouse

0
<2

= rat–NHP
<5
< 10
rare events removed (threshold)

< 20

Graphs a and b show the median PLR and iNLR values, respectively. For each species pair, the first point on each
line (i.e. < 2) shows the median PLR or iNLR for the data set with rare events below the first threshold removed
(fewer than two observations; see Results section); the second point (i.e. < 5) shows the median PLR or iNLR for the
data set with rare events below the second threshold removed (fewer than five observations; see Results section); and
so on. Removing rare events progressively from < 2 to < 20 has little effect on most of the LR values. The exceptions
are for the PLRs of the rat–mouse pairs, which roughly halve in value; and rat–mouse and rat–dog pairs for the
iNLR values, most of which increase only marginally. Notably, the NHP–human values, which indicate the degree of
evidential weight NHP tests provide for human toxicity, are one of the lowest for PLRs, and the lowest for iNLR.
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Figure 1: continued

b) Median iNLR values
2.10

2.00

1.90

1.80

Median iNLR

1.70

1.60

1.50

1.40
= NHP–dog
= NHP–human
= NHP–mouse

1.30

= NHP–rat
= dog–mouse
= dog–NHP

1.20

= dog–rat
= mouse–dog
= mouse–NHP

1.10

= mouse–rat
= rat–dog
= rat–mouse

1.00
<2

= rat–NHP
<5
< 10
rare events removed (threshold)

< 20

Graphs a and b show the median PLR and iNLR values, respectively. For each species pair, the first point on each
line (i.e. < 2) shows the median PLR or iNLR for the data set with rare events below the first threshold removed
(fewer than two observations; see Results section); the second point (i.e. < 5) shows the median PLR or iNLR for the
data set with rare events below the second threshold removed (fewer than five observations; see Results section); and
so on. Removing rare events progressively from < 2 to < 20 has little effect on most of the LR values. The exceptions
are for the PLRs of the rat–mouse pairs, which roughly halve in value; and rat–mouse and rat–dog pairs for the
iNLR values, most of which increase only marginally. Notably, the NHP–human values, which indicate the degree of
evidential weight NHP tests provide for human toxicity, are one of the lowest for PLRs, and the lowest for iNLR.

400

J. Bailey et al.

Table 3: Median LRs and ranges for each
species pair
PLR
iNLR
PLR
Species pair (median) (median) range

iNLR
range

Discussion and Conclusions

a) Values for the complete data set
NHP–human
NHP–dog
Dog–NHP
NHP–rat
Rat–NHP
NHP–mouse
Mouse–NHP
Dog–rat
Rat–dog
Dog–mouse
Mouse–dog
Rat–mouse
Mouse–rat

0
0
0
0
1.18
0
0
0
0
0
0
14.70
11.47

they may go some way toward suggesting what
might be expected from interspecies comparisons
that would suggest a high degree of evidential
weight provided by one species for another.

1.00

605

2.00

1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

3027
3027
1513
3027
1009
3027
3027
3027
3027
3027
3027
3027

1.01
9.73
1.00
20.93
3.00
4.89
1.68
6.63
3.97
2.04
27.86
10.98

b) Values calculated with rare events (< 5)
removed from the data set
NHP–human

9.39

1.02

605

0.09

NHP–dog
Dog–NHP
NHP–rat
Rat–NHP
NHP–mouse
Mouse–NHP
Dog–rat
Rat–dog
Dog–mouse
Mouse–dog
Rat–mouse
Mouse–rat

11.97
8.81
13.40
6.28
13.81
11.11
15.90
11.83
11.64
11.23
39.43
50.30

1.06
1.17
1.04
1.94
1.07
1.35
1.10
1.32
1.11
1.13
1.66
1.27

3027
96
60
56
173
173
173
173
129
146
480
472

0.39
1.98
0.19
5.55
0.40
2.31
1.21
6.56
3.57
1.60
8.28
7.92

a) While of interest, as almost all the values show the
evidential weight provided by an animal test for toxicity
in another species to be zero (the exceptions being the
rat–mouse pairs), the conclusions must be affected by the
preponderance of rare observations in the data set. For
example, 97% of the classifications were discounted for
the NHP–human species pair (see Table 2), due to
extremely low numbers of observations in one or more
species. For this reason, and to minimise any associated
bias, rare events were removed from consideration, and
LRs recalculated (see Table 3b, and graphs in Figure 1).
b) The PLRs were generally quite high, particularly for
the rat–mouse pairs, suggesting that compounds showing
toxicity in one species are also likely to be toxic in
another. This includes the NHP–human species pair.
Notably, however, these are significantly lower than
median PLRs for the dog, mouse, rabbit and rat with
respect to humans, reported in our previous analyses.
However, in common with these previous reports, high
ranges, with no obvious pattern of toxicity, suggest the
reliability of this aspect cannot be generalised or regarded
with confidence. Crucially, median iNLRs were
substantially lower, supporting the view that, when
toxicity appears to be absent in one species, this result
provides essentially no evidential weight to the likelihood
of lack of toxicity in any other species. As for the PLRs,
this includes NHPs and humans.

This analysis of animal toxicology in preclinical
drug development, complements our other two
recently-published evaluations of toxicity tests in
rats, mice, rabbits and dogs, and their relevance to
humans (8, 9). All were sorely needed, and inspired
by the lack of scientific evidence to support such
animal testing of new human drugs, and were
intended to augment previous studies suggesting
there is, in fact, evidence to the contrary (see 8, 9).
Our previous analyses have applied the apposite
statistical metrics of LRs, to data sets of unprecedented scale (though comprising, necessarily, only
publicly-available data), to determine the evidential weight for or against the toxicity of a given
compound in humans, contributed by data from
animal tests. Critically, they found that, when no
toxicity was found in the animal tests, these tests
contributed very little to no evidential weight to
the probability of lack of toxicity in humans. This
was the case for tests in dogs, mice, rabbits and
rats, and this current study found that the same
applies to tests in NHPs, meaning that the five
species commonly used in preclinical testing —
including dogs and monkeys — fail to contribute
evidential weight in this scenario. Though the data
set used in the analysis reported in this paper, and
therefore as the basis of the NHP–human species
pair analysis, was different from that used in our
previous two studies, this common theme is summarised in Table 4, which condenses all of our
analyses involving human risk of toxicity throughout the three papers. Tests in all five preclinical
species, dogs, mice, NHPs, rabbits and rats, provide little to no evidential weight. Indeed, the
iNLR value for NHPs is the lowest of all, though
the use of a different data set may account for this.
These conclusions are underpinned and bolstered by the other aspect of this paper, which
illustrates a similar lack of evidential weight provided by any species for lack of toxicity in any
other. In other words, these data, and our analyses, suggest strongly that a lack of toxicity in any
species cannot be reliably used to imply a probable
lack of toxicity in any other species. This is
absolutely crucial, because the critical observation
for deciding whether a candidate drug can proceed
to testing in humans is the absence of toxicity in
tests on animals, yet our analyses show that this
contributes no additional confidence in the eventual human outcome, but at considerable cost in
terms of animal welfare and money.
If no one species can add evidential weight in
this regard to any other species, then how can any

Predicting human drug toxicity via animal tests
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Figure 2: Box plots showing ranges of PLRs and iNLRs for all seven species pairs, with values
for rare observations (< 5) removed
103

a) PLRs

PLR

102

101

100

NHP–human

NHP–dog

NHP–rat

NHP–mouse

dog–rat

dog–mouse

rat–mouse

iNLR

101 b) iNLRs

100
NHP–human

NHP–dog

NHP–rat

NHP–mouse

dog–rat

dog–mouse

rat–mouse

The results summarised in Table 3b are shown in their entirety in these box plots, to aid visualisation and
comprehension. For each species pair, the distribution of Likelihood Ratios — a) PLRs, b) iNLRs — is illustrated via
‘box and whisker’ plots. Standard quantile box plots are shown with a logarithmic scale (log10) to incorporate higher
values, with each individual LR value plotted alongside, and ‘jittered’ for ease of visualisation. The box on each plot
is bounded by the lower (25%) and upper (75%) quartiles, and therefore represents the interquartile range, i.e. the
50% of LRs that lie either side of the median value, which itself is shown by the dashed line bisecting the box. The
mean value is indicated by the dotted line bisecting the box. The maximum and minimum LRs are shown by the
whiskers at the top and bottom of the plots, respectively. Outliers are shown as dots beyond the upper whisker, which
are greater than 1.5× the interquartile range above the upper (75%) quartile. These box plots illustrate that, for most
of the species pairs, there is a high range of LR values, but that there are high-value outliers, and that most LR
values lie toward the lower end of the range.
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Table 4: Median iNLRs and ranges for all
five preclinical species with regard
to humans

iNLR (median)

iNLR range

Rat
Mouse
Rabbit
Dog

1.82
1.39
1.12
1.10

1.02–100.0
1.03–50.0
1.01–2.33
1.01–1.92

NHP

1.02

1.00–1.08

The median iNLRs were extremely low for all the preclinical species, supporting the view that animals
provide very little or essentially no evidential weight to
this aspect of toxicity testing. Though it may appear
interesting that the value for NHPs is the lowest (and
therefore most inferior) of all five preclinical species, it
was derived from a different total data set to the other
four, which may partly account for this.

non-human species be expected to add evidential
weight to what is likely to happen in humans? At
present, the main rationale given by those who
use, for example, non-rodents such as dogs and
NHPs, is that they are not rodents — rodent data
are not trusted, so further data are sought from
other, non-rodent, species. But our analyses and
other data strongly suggest that additional data
from other species do not solve the problem of
interspecies extrapolation, and in particular,
extrapolation to humans.
While the presence of toxicity in one species may
sometimes add evidential weight for risk of toxicity
in another, the LRs are extremely inconsistent,
varying substantially for different classes of drugs
and their effects. As we have previously commented, this suggests that this aspect of animal
toxicity tests cannot be considered robust and reliable for any specific new drug, particularly when
one considers the prior evidence to the contrary,
suggesting that animal toxicity tests are poorly
predictive of human risk (see our previous related
papers [8, 9] for references). At the very least, the
fact that there is conflicting evidence in this
respect, and that our analyses are, necessarily,
based on the relatively limited publicly-available
data, demands that further analyses of proprietary
data, conducted and/or overseen by industry, are
conducted in a transparent, and preferably
independent, manner.
As we have argued previously, all of this must
have practical and urgent implications for the
future use of animals in toxicity testing, especially
in the pharmaceutical industry, because poor
iNLRs mean that toxic compounds are progressing
to testing in humans, only to fail in clinical trials
or soon after approval for marketing. This is not

conjecture — it is widely acknowledged, and evidenced by adverse drug reactions and new drug
failures at record levels, after an inexorable rise
over the past two decades (4, 5, 14–20). Further,
this is not something that can be ‘fixed’ by improving the rigour of the animal tests. There is a scientific basis for this level of failure, namely, major
interspecies differences in the cytochrome P450
enzymes (CYP), which are involved in the metabolism of more than 90% of drugs (21). This is discussed in our recent papers, but briefly, increasing
(and long overdue) comparative analyses of CYPs
across species, including dogs and monkeys, are
revealing important differences (which are often
minor in nature, but significant functionally), with
important consequences for the extrapolation of
animal data to humans. Indeed, such differences
also seem prevalent within species, and are a basis
for human variability in susceptibility to adverse
drug reactions. So, even if, for the sake of argument, any one or a combination of non-human
species could reliably predict effects in humans —
which ‘humans’ would they be, given the vast scale
of human polymorphism?
It is increasingly clear that the animal testing of
human drugs is not fit-for-purpose, and this is
especially true in the light of the astounding array
of directly human-relevant methods now available
to science for testing new drugs (see, for example,
22, 23). In combination with an unprecedented
level of public concern over the use of animals in
science (24), and the high ethical costs of doing so,
we conclude that the preclinical testing of pharmaceuticals in animals cannot currently be justified,
ethically or scientifically. At the very least, it is
incumbent on the pharmaceutical industry and its
regulators to take on board the concerns highlighted by our work, and to augment it via their
own studies, using proprietary data that are not
publicly-available, as a matter of urgency.
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